MicroPort NeuroTech Limited (2172.HK)

7.050 -0.030 (-0.42%) At close: 04:08PM HKT

MicroPort NeuroTech Limited

Zhangjiang High-tech Park
No. 1661 Zhangdong Road Pudong New Area
Shanghai
China
86 21 3895 4600
https://www.medneurotech.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 571

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Zhiyong Xie	CEO, Executive Director & Chairman of MicroPort NeuroTech	1.28M	N/A	1976
Mr. Yiqun Wang	Senior VP & Executive Director	1.36M	N/A	1965
Ms. Zhuoping Hou	Advanced Director of Finance	N/A	N/A	1978
Dr. Wangcai Liao	Chief Technology Officer	N/A	N/A	1964
Ms. Zaoli Wu	Senior Director of Human Resources & Administration	N/A	N/A	1983
Mr. Lei Duan	Chief Marketing Officer and SVP of Sales & Promotion of Neurovascular Disease Treatment Solutions	N/A	N/A	1982
Ms. Yin Shan Hui A.C.I.S., A.C.S., HKICS, ICSA	Company Secretary	N/A	N/A	1969

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. The company offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. It also offers NeuroGuard, NuFairy, a absorbable coil embolization system; and liquid embolic agent, a cerebral arteriovenous malformations. In addition, the company provides APOLLO, an intracranial stent a balloon-expandable stent to treat intracranial atherosclerotic disease; Bridge, a rapamycin target eluting vertebral artery stent system; and Diveer, an intracranial balloon catheter to treat cerebral atherosclerosis stenosis. Further, it offers Neurohawk, a stent thrombectomy device; X-Track, and distal access catheter product; W-track, an intracranial aspiration catheter; and balloon protection guide catheter; and Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. Additionally, the company provides Carotid Stent System, Asahi Neurovascular Guidewires and U-track support catheter. Furthermore, it offers Fastrack Microcatheter System, Veyronwire Neurovascular Guide Wire, 17 Microcatheter, Distal Protection Device, and QUEEN-track Microcatheter, a hydrophilic coating device for stimulation of blood vessels. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.

Corporate governance

MicroPort NeuroTech Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.